Benefit of thrombolytic therapy in patients with acute stroke, who are on anticoagulant treatment, is not well addressed. The aim of this study was to investigate whether apixaban can modify the thrombolytic efficacy of alteplase in vitro. Static and flow models and two variants of red blood cell (RBC) dominant clots, with and without apixaban, were used. Clots were prepared from the blood of healthy human donors and subsequently exposed to alteplase treatment. Apixaban and alteplase were used in clinically relevant concentrations. Clot lysis in the static model was determined both by clot weight and spectrophotometric determination of RBC release. Clot lysis in the flow model was determined by measuring recanalization time, clot length and spectrophotometric determination of RBC release. In the static model, clots without apixaban; compared to those with apixaban had alteplase-induced mass loss 54 ± 8% vs. 53 ± 8%, p = 1.00; RBC release 0.14 ± 0.04 vs. 0.12 ± 0.04, p = 0.14, respectively. Very similar results were obtained if plasma was used instead of physiological buffered saline as the incubation medium. In the flow model, clot lysis without apixaban; compared to those with apixaban was as follows: recanalization time 107 ± 46 min vs. 127 ± 31 min, p = 1.00; recanalization frequency 90 ± 22% vs. 90 ± 22%, p = 1.00; clot volume reduction 32 ± 15% vs. 34 ± 10%, p = 1.00; RBC release 0.029 ± 0.007 vs. 0.022 ± 0.007, p = 0.16, respectively. Apixaban had no positive effect on alteplase-induced thrombolysis in both the in vitro static and flow models. Our data support current clinical practice, such that thrombolysis is contraindicated in stroke treatment for patients who have been treated with anticoagulants.

Center of Biomolecular and Cell Engineering International Clinical Research Center St Anne's University Hospital Brno Brno Czechia

Department of Biochemistry Faculty of Science Masaryk University Brno Czechia

Institute of Biophysics of the Czech Academy of Sciences Brno Czechia

Neurology Department International Clinical Research Center St Anne's University Hospital Brno Brno Czechia

Zobrazit více v PubMed

Acheampong P., Ford G. A. (2012). Pharmacokinetics of alteplase in the treatment of ischaemic stroke. Expert Opin. Drug Metab. Toxicol. 8 (2), 271–281. 10.1517/17425255.2012.652615 PubMed DOI

Artang R., Anderson M., Riley P., Nielsen J. D. (2017). Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res. Pract. Thromb. Haemost. 1 (2), 194–201. 10.1002/rth2.12044 PubMed DOI PMC

Byon W., Garonzik S., Boyd R. A., Frost C. E. (2019). Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review. Clin. Pharmacokinet. 58 (10), 1265–1279. 10.1007/s40262-019-00775-z PubMed DOI PMC

Carter R. L. R., Talbot K., Hur W. S., Meixner S. C., Van Der Gugten J. G., Holmes D. T., et al. (2018). Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. J. Thromb. Haemost. 16 (11), 2276–2288. 10.1111/jth.14281 PubMed DOI

Chao Y. T., Hu C. J., Chan L. (2019). Thrombolysis in an acute ischemic stroke patient with rivaroxaban anticoagulation: A case report. Medicine (Baltimore) 98 (8), e14560–3. 10.1097/MD.0000000000014560 PubMed DOI PMC

Connolly S. J., Eikelboom J., Joyner C., Diener H. C., Hart R., Golitsyn S., et al. (2011). Apixaban in Patients with Atrial Fibrillation. N. Engl. J. Med. 364, 806–817. 10.1056/NEJMoa1007432 PubMed DOI

Connolly S. J., Ezekowitz M. D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361, 1139–1151. 10.1056/NEJMoa0905561 PubMed DOI

Diamond S. L. (1999). Engineering design of optimal strategies for blood clot dissolution. Annu. Rev. Biomed. Eng. 1, 427–462. 10.1146/annurev.bioeng.1.1.427 PubMed DOI

Elnager A., Abdullah W. Z., Hassan R., Idris Z., Wan Arfah N., Sulaiman S. A., et al. (2014). In Vitro Whole Blood Clot Lysis for Fibrinolytic Activity Study Using D-Dimer and Confocal Microscopy. Adv. Hematol. 2014, 814684–814688. 10.1155/2014/814684 PubMed DOI PMC

Escolar G., Fernandez-Gallego V., Arellano-Rodrigo E., Roquer J., Reverter J. C., Sanz V. V., et al. (2013). Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One 8 (11), e78696. 10.1371/journal.pone.0078696 PubMed DOI PMC

Farag M., Niespialowska-Steuden M., Okafor O., Artman B., Srinivasan M., Khan A., et al. (2016). Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets 27 (7), 687–693. 10.3109/09537104.2016.1158402 PubMed DOI

Granger C. B., Alexander J. H., McMurray J. J., Lopes R. D., Hylek E. M., Hanna M., et al. (2011). Apixaban versus Warfarin in Patients with Atrial Fibrillation. N. Engl. J. Med. 365, 981–992. 10.1056/NEJMoa1107039 PubMed DOI

Harpaz D., Chen X., Francis C. W., Marder V. J., Meltzer R. S. (1993). Ultrasound enhancement of thrombolysis and reperfusion in vitro . J. Am. Coll. Cardiol. 21 (6), 1507–1511. 10.1016/0735-1097(93)90331-t PubMed DOI

Hosokawa K., Ohnishi T., Sameshima H., Miura N., Koide T., Maruyama I., et al. (2014). Comparative Evaluation of Direct Thrombin and Factor Xa Inhibitors with Antiplatelet Agents under Flow and Static Conditions: An in Vitro Flow Chamber Model. PLoS One 9 (1), e86491. 10.1371/journal.pone.0086491 PubMed DOI PMC

Ishihara H., Torii H., Imoto H., Oka F., Sadahiro H., Suzuki M. (2014). Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with rivaroxaban. J. Stroke Cerebrovasc. Dis. 23 (10), e457–459. 10.1016/j.jstrokecerebrovasdis.2014.07.008 PubMed DOI

Jiang X., Crain E. J., Luettgen J. M., Schumacher W. A., Wong P. C. (2009). Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro . Thromb. Haemost. 101 (4), 780–782. 10.1160/th08-07-0486 PubMed DOI

Jin C., Huang R. J., Peterson E. D., Laskowitz D. T., Hernandez A. F., Federspiel J. J., et al. (2018). Intravenous tPA (Tissue-type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-vitamin K Antagonist Oral Anticoagulants Preceding Stroke. Stroke 49 (9), 2237–2240. 10.1161/STROKEAHA.118.022128 PubMed DOI PMC

Kim Y. D., Nam H. S., Kim S. H., Kim E. Y., Song D., Kwon I., et al. (2015). Time-Dependent Thrombus Resolution after Tissue-type Plasminogen Activator in Patients with Stroke and Mice. Stroke 46 (7), 1877–1882. 10.1161/STROKEAHA.114.008247 PubMed DOI

Lau Y. C., Xiong Q., Shantsila E., Lip G. Y., Blann A. D. (2016). Effects of Non-vitamin K Antagonist Oral Anticoagulants on Fibrin Clot and Whole Blood Clot Formation, Integrity and Thrombolysis in Patients with Atrial Fibrillation. J. Thromb. Thrombolysis 42 (4), 535–544. 10.1007/s11239-016-1399-3 PubMed DOI PMC

Patel M. R., Mahaffey K. W., Garg J., Pan G., Singer D. E., Hacke W., et al. (2011). Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N. Engl. J. Med. 365, 883–891. 10.1056/NEJMoa1009638 PubMed DOI

Pinto D. J., Orwat M. J., Koch S., Rossi K. A., Alexander R. S., Smallwood A., et al. (2007). Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-Yl)phenyl)-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J. Med. Chem. 50 (22), 5339–5356. 10.1021/jm070245n PubMed DOI

Prasad S., Kashyap R. S., Deopujari J. Y., Purohit H. J., Taori G. M., Daginawala H. F. (2006). Development of an in vitro model to study clot Lysis activity of thrombolytic drugs. Thromb. J. 4 (14), 14–4. 10.1186/1477-9560-4-14 PubMed DOI PMC

Pujadas-Mestres L., Lopez-Vilchez I., Arellano-Rodrigo E., Reverter J. C., Lopez-Farre A., Diaz-Ricart M., et al. (2017). Differential Inhibitory Action of Apixaban on Platelet and Fibrin Components of Forming Thrombi: Studies with Circulating Blood and in a Platelet-Based Model of Thrombin Generation. PLoS One 12 (2), e0171486. 10.1371/journal.pone.0171486 PubMed DOI PMC

Šaňák D. (2018). Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A Real-World Clinical Experience. J. Stroke Cerebrovasc. Dis. 27 (9), 2479–2483. PubMed

Seiffge D. J., Hooff R. J., Nolte C. H., Béjot Y., Turc G., Ikenberg B., et al. (2015). Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 132 (13), 1261–1269. 10.1161/CIRCULATIONAHA.115.015484 PubMed DOI

Shahjouei S., Tsivgoulis G., Goyal N., Sadighi A., Mowla A., Wang M., et al. (2020). Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis. Stroke 51 (2), 533–541. 10.1161/STROKEAHA.119.026426 PubMed DOI

Spinthakis N., Gue Y., Farag M., Srinivasan M., Wellsted D., Arachchillage D. R. J., et al. (2019). Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. Europace 21 (9), 1297–1306. 10.1093/europace/euz176 PubMed DOI PMC

Sugihara H., Idemoto Y., Kuwano T., Nagata Y., Morii J., Sugihara M., et al. (2016). Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System®: In Vitro and Ex Vivo Studies. J. Clin. Med. Res. 8 (12), 899–907. 10.14740/jocmr2773w PubMed DOI PMC

Sutton J. T., Ivancevich N. M., Perrin S. R., Vela D. C., Holland C. K. (2013). Clot Retraction Affects the Extent of Ultrasound-Enhanced Thrombolysis in an Ex Vivo Porcine Thrombosis Model. Ultrasound Med. Biol. 39 (5), 813–824. 10.1016/j.ultrasmedbio.2012.12.008 PubMed DOI PMC

Talbot K., Meixner S. C., Pryzdial E. L. (2013). Proteolytic Modulation of Factor Xa-antithrombin Complex Enhances Fibrinolysis in Plasma. Biochim. Biophys. Acta 1834 (6), 989–995. 10.1016/j.bbapap.2013.02.007 PubMed DOI

Tsivgoulis G., Kargiotis O., De Marchis G., Kohrmann M., Sandset E. C., Karapanayiotides T., et al. (2021). Off-label use of intravenous thrombolysis for acute ischemic stroke: a critical appraisal of randomized and real-world evidence. Ther. Adv. Neurol. Disord. 14, 1756286421997368. 10.1177/1756286421997368 PubMed DOI PMC

Tsivgoulis G., Safouris A. (2017). Intravenous Thrombolysis in Acute Ischemic Stroke Patients Pretreated with Non-vitamin K Antagonist Oral Anticoagulants: An Editorial Review. Stroke 48 (7), 2031–2033. 10.1161/STROKEAHA.117.017206 PubMed DOI

Varin R., Mirshahi S., Mirshahi P., Klein C., Jamshedov J., Chidiac J., et al. (2013). Whole Blood Clots Are More Resistant to Lysis Than Plasma Clots--Greater Efficacy of Rivaroxaban. Thromb. Res. 131 (3), e100–9. 10.1016/j.thromres.2012.11.029 PubMed DOI

Zangerle A., Kiechl S., Spiegel M., Furtner M., Knoflach M., Werner P., et al. (2007). Recanalization after Thrombolysis in Stroke Patients: Predictors and Prognostic Implications. Neurology 68 (1), 39–44. 10.1212/01.wnl.0000250341.38014.d2 PubMed DOI

A collateral circulation in ischemic stroke accelerates recanalization due to lower clot compaction

Factors influencing the efficacy of recombinant tissue plasminogen activator: Implications for ischemic stroke treatment

Computer-aided engineering of staphylokinase toward enhanced affinity and selectivity for plasmin